Aisling Capital Management LP
Top Portfolio Positions
13 positions ·
$476,288,949 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| BBIO |
BridgeBio Pharma, Inc.
Healthcare
|
5,089,611 | $377,954,512 | 79.35% | |
| SNDX |
Syndax Pharmaceuticals Inc
Healthcare
|
1,316,806 | $30,760,588 | 6.46% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
1,555,664 | $25,590,672 | 5.37% | |
| BCAX |
Bicara Therapeutics Inc.
Healthcare
|
568,919 | $11,315,798 | 2.38% | |
| BBOT |
BridgeBio Oncology Therapeutics, Inc.
Healthcare
|
1,018,018 | $9,111,261 | 1.91% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
1,432,336 | $7,920,818 | 1.66% | |
| SRRK |
Scholar Rock Holding Corp
Healthcare
|
77,031 | $3,786,843 | 0.80% | |
| BMEA |
Biomea Fusion, Inc.
Healthcare
|
2,048,757 | $3,134,598 | 0.66% | |
| EPRX |
Eupraxia Pharmaceuticals Inc.
Healthcare
|
325,000 | $2,353,000 | 0.49% | |
| URGN |
UroGen Pharma Ltd.
Healthcare
|
108,000 | $1,941,840 | 0.41% |
Portfolio Trend
25 quarters · across all stocks
Holdings in SNDX
Shares Held
Position Value (USD)
25 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $30,760,588 | 1,316,806 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $27,666,094 | 1,316,806 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $20,259,060 | 1,316,806 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $12,331,888 | 1,316,806 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $12,592,125 | 1,025,000 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $13,550,500 | 1,025,000 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $19,731,250 | 1,025,000 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $21,043,250 | 1,025,000 | Shares | Sole | 2024-08-08 | |
| 2024-03-31 | $24,395,000 | 1,025,000 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $22,150,250 | 1,025,000 | Shares | Sole | 2024-02-07 | |
| 2023-09-30 | $14,883,000 | 1,025,000 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $21,453,250 | 1,025,000 | Shares | Sole | 2023-08-11 | |
| 2023-03-31 | $21,648,000 | 1,025,000 | Shares | Sole | 2023-05-09 | |
| 2022-12-31 | $26,086,250 | 1,025,000 | Shares | Sole | 2023-02-09 | |
| 2022-09-30 | $24,630,750 | 1,025,000 | Shares | Sole | 2022-11-03 | |
| 2022-06-30 | $19,721,000 | 1,025,000 | Shares | Sole | 2022-08-10 | |
| 2022-03-31 | $17,814,500 | 1,025,000 | Shares | Sole | 2022-05-10 | |
| 2021-12-31 | $22,437,250 | 1,025,000 | Shares | Sole | 2022-02-18 | |
| 2021-09-30 | $19,587,750 | 1,025,000 | Shares | Sole | 2021-11-12 | |
| 2021-06-30 | $17,599,250 | 1,025,000 | Shares | Sole | 2021-08-06 | |
| 2021-03-31 | $22,919,000 | 1,025,000 | Shares | Sole | 2021-05-14 | |
| 2020-12-31 | $22,796,000 | 1,025,000 | Shares | Sole | 2021-02-05 | |
| 2020-09-30 | $15,129,000 | 1,025,000 | Shares | Sole | 2020-11-12 | |
| 2020-06-30 | $15,190,500 | 1,025,000 | Shares | Sole | 2020-08-10 | |
| 2020-03-31 | $9,598,750 | 875,000 | Shares | Sole | 2020-05-11 | |
| No 13F history on record for this holder in this stock. | ||||||